Myriad Genetics Inc. (NASDAQ: MYGN) is rising sharply this morning after earnings, or technically after it reported a smaller than forecast drop in profit. So far we have seen one upgrade: Canaccord raised its rating to BUY from HOLD. At 8:55 AM EST we have seen some 156,000 shares trade hands and the have is up 10.3% at $28.55. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment